HR Execs on the Move

Capcium

www.capcium.com

 
Capcium is a value-add pharmaceutical grade manufacturer of softgel capsules and other novel delivery technologies that was born from a strong desire to transform the cannabis, pharmaceutical, nutraceutical, over the counter (OTC) and cosmetics industries by setting new standards in the development and manufacturing of finished consumer products.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.capcium.com
  • 1675 Rte Transcanadienne Suite 135
    Dorval, QC CAN H9P 1J1
  • Phone: 514.339.5986

Executives

Name Title Contact Details
Jennifer Pinsky
Director of Human Resources Profile

Similar Companies

Tapestry Pharmaceuticals

Tapestry Pharmaceuticals, Inc. is a Boulder, CO-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Family Services of Chemung Cty.

Family Services of Chemung County is located at 1019 East Water Street, Elmira, NY 14901. We offer professional counseling, crisis, case maangement, home care and other community based supportive services to youth and adults.

BrainsWay

BrainsWay is an Israeli company with international operations that is engaged in the development of a medical device that uses H-coil for deep transcranial magnetic stimulation as a noninvasive treatment for depression.

MAPS Public Benefit Corporation

MAPS Public Benefit Corporation (MAPS PBC) catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics.

BioXcel Therapeutics

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company`s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company`s two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.